Companies
Anika Therapeutics
Anika is a global leader in osteoarthritis pain management and early-intervention regenerative orthopedics, reporting full-year 2025 results with HA-based viscosupplementation (Monovisc, Cingal) for knee osteoarthritis.
- Country
- United States
- Ticker
- Nasdaq:ANIK
OA viscosupplementation
FDA approved
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biosynthetic hyaluronic acid | specialty-fine-chem | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.